Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance [0.03%]
利用转录组学发现天然产物以克服获得性癌症抗药性
Heerim Yeo,Sang-Yun Kim,Sang-Min Park
Heerim Yeo
Targeted cancer therapy is often compromised by the development of acquired drug resistance. Beyond genetic mutations, recent studies underscore the role of non-genetic plasticity and adaptive network rewiring in driving this resistance. Ov...
Exploration of recent advancements of nanoparticle-based therapeutics emphasis on diabetic-related chronic wound management: a comprehensive review [0.03%]
基于纳米颗粒的治疗手段在糖尿病相关慢性伤口管理中的最新进展探索：全面综述
Esraa M Elshazly,Mona G Arafa,Samia A Nour
Esraa M Elshazly
The skin is frequently subjected to injuries and disorders encompassing both acute and chronic wounds. Chronic wounds, including diabetic wounds, pose significant clinical problems due to prolonged and ineffective healing processes. Traditi...
Constituents from Caragana jubata (Pall.) Poir. and their in vitro neuroprotective effects [0.03%]
Caragana jubata (Pall.) Poir. 的成分及其体外神经保护活性研究
Xiaohong Wang,Hailian Yuan,Siyi Wang et al.
Xiaohong Wang et al.
The present study aimed to isolate compounds from Caragana jubata (Pall.) Poir. and evaluate their in vitro neuroprotective effects. The compounds were isolated by various column chromatographic techniques and semipreparative HPLC. The stru...
Yang Zhao,Xiao-Xin Zhu,Xiaohuan Li et al.
Yang Zhao et al.
The genus Croton, a member of the Euphorbiaceae family, comprises nearly 1300 species globally, predominantly inhabiting tropical and subtropical regions. Certain species of Croton are renowned for their significant medicinal properties. Di...
Inhibition of RBPJ transcription complex promotes IL-17 and IFN-γ secretion by CD4⁺ T cells in hepatocellular carcinoma [0.03%]
RBPJ转录复合物的抑制促进肝细胞癌中CD4⁺T细胞分泌IL-17和IFN-γ
Yuxin Yao,Xinyu Zhang,Hao Wu et al.
Yuxin Yao et al.
Hepatocellular carcinoma (HCC) is characterized by an immunosuppressive tumor microenvironment (TME), indicating that immune cell activation is a promising approach. The use of γ-secretase inhibitors (GSIs) to control high Notch signaling ...
Pharmacological targeting of HDAC/BET pathway enhances 5-FU efficacy in esophageal squamous cancer cells [0.03%]
表观遗传药物HDAC和BET抑制剂可通过表观遗传重编程增强食管鳞癌细胞中5-氟尿嘧啶的疗效
Xiaqing Xu,Qian Liu,Feifei Yang et al.
Xiaqing Xu et al.
5-Fluorouracil (5-FU) remains the most commonly used first-line chemotherapeutic agent for the treatment of esophageal cancer (EC), but its therapeutic efficacy is unsatisfactory. In this study, we found that 5% of ESCC cells survived the t...
Title: Resveratrol ameliorates liver fibrosis by inhibiting ATF4 to regulate glutamine metabolism in hepatic stellate cells [0.03%]
白藜芦醇通过抑制ATF4来调节肝星状细胞中的谷氨酰胺代谢从而改善肝纤维化
Huiya Ying,Yixiao Wang,Dandan Zhu et al.
Huiya Ying et al.
Resveratrol has been shown to mitigate liver fibrosis by inhibiting the activation of hepatic stellate cells (HSCs). However, the precise mechanisms remain incompletely understood. Resveratrol demonstrates therapeutic potential in alleviati...
Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases [0.03%]
探讨细胞色素P450酶及其抑制剂在癌症和非增殖性人类疾病中的作用
Hyein Lee,Yeo-Jung Kwon,Young-Jin Chun
Hyein Lee
Cytochrome P450 (CYP) enzymes are crucial for metabolizing various compounds, including therapeutic drugs. Metabolites generated through CYP-mediated pathways have been increasingly recognized as key contributors to the pathogenesis and pro...
Boron-containing anticancer agents: a target-centric review of structure-activity relationships and clinical pipeline [0.03%]
含硼抗肿瘤药物的结构活性关系及临床药物管线的靶点总结性回顾
Haeun Lee,Mingi Kim,Byungsun Jeon
Haeun Lee
Boron, a versatile element historically underexplored in medicinal chemistry, has recently garnered prominence for its unique chemical properties that enable the design of innovative therapeutic compounds. The success of boron-containing dr...
Jie Hu,Songyang Zhong,Huayu Sun et al.
Jie Hu et al.
Estrogen receptors (ERs) are expressed in approximately 70% of breast cancer patients and serve as pivotal therapeutic targets. ER-targeting agents like selective estrogen receptor modulators (SERMs) and selective estrogen receptor degrader...